Literature DB >> 10738270

Aberrations of the K-ras, p53, and APC genes in extrahepatic bile duct cancer.

T Suto1, W Habano, T Sugai, N Uesugi, O Funato, S Kanno, K Saito, S i Nakamura.   

Abstract

BACKGROUND AND OBJECTIVES: The genetic alterations involved in extrahepatic bile duct (EHBD) cancer are poorly understood. Our aim was to identify aberrations of the K-ras, p53, and APC genes in EHBD cancer.
METHODS: We investigated aberrations of these genes in 52 EHBD cancers using polymerase chain reaction (PCR) single-strand conformation polymorphism analysis, followed by direct sequence determination and a PCR restriction fragment length polymorphism assay.
RESULTS: The K-ras, p53, and APC genes were mutated in 9.6%, 32.7%, and 0% of EHBD cancers, respectively. Loss of heterozygosity at the p53 and APC gene loci was identified in 15.6% and 38.5% of EHBD cancers, respectively.
CONCLUSIONS: Our results suggest that an unknown suppressor gene on 5q other than the APC gene may be responsible for EHBD cancer.

Entities:  

Mesh:

Year:  2000        PMID: 10738270     DOI: 10.1002/(sici)1096-9098(200003)73:3<158::aid-jso9>3.0.co;2-n

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  11 in total

1.  CpG island hypermethylation and repetitive DNA hypomethylation in premalignant lesion of extrahepatic cholangiocarcinoma.

Authors:  Baek-hui Kim; Nam-Yun Cho; So Hyun Shin; Hyeong-Ju Kwon; Ja June Jang; Gyeong Hoon Kang
Journal:  Virchows Arch       Date:  2009-09-10       Impact factor: 4.064

Review 2.  Genetics of biliary tract cancers and emerging targeted therapies.

Authors:  Aram F Hezel; Vikram Deshpande; Andrew X Zhu
Journal:  J Clin Oncol       Date:  2010-06-14       Impact factor: 44.544

3.  Comparison of the novel quantitative ARMS assay and an enriched PCR-ASO assay for K-ras mutations with conventional cytology on endobiliary brush cytology from 312 consecutive extrahepatic biliary stenoses.

Authors:  N T van Heek; S J Clayton; P D J Sturm; J Walker; D J Gouma; L A Noorduyn; G J A Offerhaus; J C Fox
Journal:  J Clin Pathol       Date:  2005-12       Impact factor: 3.411

Review 4.  Molecular genetics and targeted therapeutics in biliary tract carcinoma.

Authors:  Eric I Marks; Nelson S Yee
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

5.  Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.

Authors:  Darrell R Borger; Kenneth K Tanabe; Kenneth C Fan; Hector U Lopez; Valeria R Fantin; Kimberly S Straley; David P Schenkein; Aram F Hezel; Marek Ancukiewicz; Hannah M Liebman; Eunice L Kwak; Jeffrey W Clark; David P Ryan; Vikram Deshpande; Dora Dias-Santagata; Leif W Ellisen; Andrew X Zhu; A John Iafrate
Journal:  Oncologist       Date:  2011-12-16       Impact factor: 5.837

6.  Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.

Authors:  Ymera Pignochino; Ivana Sarotto; Caterina Peraldo-Neia; Junia Y Penachioni; Giuliana Cavalloni; Giorgia Migliardi; Laura Casorzo; Giovanna Chiorino; Mauro Risio; Alberto Bardelli; Massimo Aglietta; Francesco Leone
Journal:  BMC Cancer       Date:  2010-11-18       Impact factor: 4.430

7.  Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.

Authors:  Vikram Deshpande; Afamefuna Nduaguba; Stephanie M Zimmerman; Sarah M Kehoe; Laura E Macconaill; Gregory Y Lauwers; Cristina Ferrone; Nabeel Bardeesy; Andrew X Zhu; Aram F Hezel
Journal:  BMC Cancer       Date:  2011-02-08       Impact factor: 4.430

8.  p63 and p73 expression in extrahepatic bile duct carcinoma and their clinical significance.

Authors:  Seung-Mo Hong; Hyungjun Cho; Christopher A Moskaluk; Eunsil Yu; Alexander I Zaika
Journal:  J Mol Histol       Date:  2007-03-24       Impact factor: 3.156

Review 9.  New and emerging treatment options for biliary tract cancer.

Authors:  Marcus S Noel; Aram F Hezel
Journal:  Onco Targets Ther       Date:  2013-10-30       Impact factor: 4.147

10.  Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.

Authors:  A F Hezel; M S Noel; J N Allen; T A Abrams; M Yurgelun; J E Faris; L Goyal; J W Clark; L S Blaszkowsky; J E Murphy; H Zheng; A A Khorana; G C Connolly; O Hyrien; A Baran; M Herr; K Ng; S Sheehan; D J Harris; E Regan; D R Borger; A J Iafrate; C Fuchs; D P Ryan; A X Zhu
Journal:  Br J Cancer       Date:  2014-06-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.